Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
QALY Control: House Bill Would Ban Cost-Effectiveness Tool In US Programs
Mar 16 2023
•
By
Michael McCaughan
If QALYs can't be used, then how should cost-effectiveness be measured? • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
More from Pricing Debate
More from Market Access